|1.||Vonderheide, Robert H: 5 articles (01/2014 - 03/2007)|
|2.||O'Dwyer, Peter J: 2 articles (11/2013 - 03/2007)|
|3.||Rüter, Jens: 2 articles (11/2010 - 01/2009)|
|4.||Huhn, Richard D: 2 articles (11/2010 - 03/2007)|
|5.||Antonia, Scott J: 2 articles (11/2010 - 03/2007)|
|6.||Hasani, A: 1 article (12/2015)|
|7.||Millward, M J: 1 article (12/2015)|
|8.||McCoy, M J: 1 article (12/2015)|
|9.||Lake, R A: 1 article (12/2015)|
|10.||McDonnell, A M: 1 article (12/2015)|
07/01/2011 - "These studies suggest that CP-870,893 has the potential to be efficacious against a wide range of tumor types through both direct and immune-mediated effects."
01/01/2009 - "Although clinical translation of these findings for patients with cancer has been previously limited due to the lack of a suitable and available drug, promising clinical results are now emerging from phase I studies of the agonist CD40 monoclonal antibody CP-870,893. "
07/01/2011 - "The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice."
11/15/2010 - "Weekly infusions of the agonist CD40 antibody CP-870,893 were well-tolerated, but there was little clinical activity in advanced cancer patients. "
11/15/2010 - "Single-dose infusion of the agonistic anti-CD40 monoclonal antibody (mAb) CP-870,893 accomplishes immune activation and clinical responses in patients with advanced cancers, but repeat dosing of this agent has not been reported. "
|2.||B-Cell Lymphoma (Lymphoma, B Cell)
|3.||Melanoma (Melanoma, Malignant)
10/01/2010 - "In these studies, biopsies of patients with primary and metastatic melanoma, short-term cultures, and established melanoma cell lines were analyzed for CD40 expression using a combination of methods including immunohistochemistry, flow cytometry, and gene expression profiling, and the cytotoxic effects of the anti-CD40 antibody CP-870,893 on melanoma cell lines were tested using cell viability assays. "
10/01/2010 - "Treatment with increasing concentrations of CP-870,893 had no antitumor activity against either CD40-positive or negative melanoma cell lines. "
10/01/2010 - "CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870,893."
01/01/2014 - "CP-870,893 is a fully human anti-CD40 mAb, selected in part because it is an IgG2 which is presumed to have poor reactivity with FcR; however, CP-870,893 has been evaluated in multiple clinical trials with beneficial activity in patients with melanoma, pancreatic and other cancers. "
11/15/2013 - "This phase I study investigated the maximum-tolerated dose (MTD), safety, pharmacodynamics, immunologic correlatives, and antitumor activity of CP-870,893, an agonist CD40 antibody, when administered in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma (PDA). "
|1.||Immunoglobulin G (IgG)
|3.||Biological Markers (Surrogate Marker)